FGP
CRMD icon

Freestone Grove Partners’s CorMedix CRMD Stock Holding History

Freestone Grove Partners’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Buy
33,335
+23,003
+223% +$182K ﹤0.01% 779
2026
Q1 		$70.2K Buy
+10,332
New +$76.4K ﹤0.01% 823

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Freestone Grove Partners's CRMD Position: Q2 2026 in Review

Freestone Grove Partners increased its CorMedix (CRMD) stake by 223% in Q2 2026, buying an estimated $182K and bringing the position to 33,335 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #779.

Freestone Grove Partners first reported a position in CRMD in Q1 2026 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Freestone Grove Partners held 33,335 shares of CorMedix worth $262K as of Q2 2026.
  • Freestone Grove Partners bought 23,003 CorMedix shares in Q2 2026, an estimated $182K.
  • CorMedix made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #779 holding.
  • Freestone Grove Partners first reported a position in CorMedix in Q1 2026 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.